Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Knockdown of DHRS7 in LNCaP cells

ABSTRACT: Knockdown of DHRS7 in the prostate cancer cell line LNCaP was performed for 24h, 36h, and 48h using siRNA.

INSTRUMENT(S): Orbitrap Fusion Lumos

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Epithelial Cell, Cell Culture

DISEASE(S): Prostate Adenocarcinoma

SUBMITTER: Simon Stuecheli

LAB HEAD: Alex Odermatt

PROVIDER: PXD031229 | Pride | 2022-07-07

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	0h_NT1_vs_24H_C_vs_24h_KD.msf	Msf
	20170502_Swissprot_Human.fasta	Fasta
	20180104_0h_NT1_Fr1_01.raw	Raw
	20180104_0h_NT1_Fr1_02.raw	Raw
	20180104_0h_NT1_Fr1_03.raw	Raw

Items per page:

1 - 5 of 167

Similar Datasets

Knockdown studies of TAPIR lncRNAs in LNCaP cells

Project description:To unravel the molecular function of TAPIR-1 and -2, four different specific siRNAs were used to knockdown the TAPIR-transcripts in LNCaP-cells. Gene expression changes upon knockdown of TAPIR was assessed by Agilent SurePrint G3 Human Gene Expression Arrays at 24h and 48h after treatment.

2020-06-17 | GSE134015 | GEO

S-acylproteomic analysis of human prostate cancer LNCaP cells by LB-ABE

Project description:Deep S-acylproteomic analysis of LNCaP cells by coupling LB-ABE with label-free quantitative proteomics

2021-09-08 | PXD013187 | Pride

Siomycin A treatment in prostate cancer cell lines PC3 and LNCaP

Project description:Siomycin A treatment in prostate cancer cell lines resulted in a concurrent inhibition of specific cell cycle genes and strongly impaired cell viability. Illumina microarray experiments were done using PC3 and LNCaP cell lines treated with 0.5 microM Siomaycin A either 24h or 48h in triplicates.

2012-10-19 | E-GEOD-36531 | biostudies-arrayexpress

Expression data from androgen treated LNCaP cells

Project description:Androgens are required for the development of normal prostate, and they are also linked to the development of prostate cancer. We used microarrays to understand the role of androgen in an androgen dependent, androgen receptor (AR) positive human metastatic cell line, LNCaP. LNCaP cells were grown in RPMI medium and they were subjected to stay in phenol-red free, RPMI with charcoal stripped serum for 48h. Synthetic androgen R1881 was added and the cells were allowed to grow for 48h. Control cells were given with corresponding amount of ethanol as vehicle which is used for the solubilization of R1881. Cells were harvested and RNA was isolated for microarray analysis.

2009-12-29 | E-GEOD-17044 | biostudies-arrayexpress

50uM Casodex treatment of LNCaP Prostate Cancer cells

Project description:Genome wide expression changes following 50uM Casodex treatment were investigated to determine regulatory targets commonly overlooked in gene function specific microarrays and for comparison of the effects of the mutant androgen receptor (AR) LNCaP cell line against the wild-type AR expressing PC-346C cells. LNCaP Prostate Cancer cells were treated for a period of 48h with or without 50uM Casodex following a 24h seeding period. At the selected time point, total RNA was harvested from the cells for hybridization and analysis by Nimblgen Systems Inc using the homo sapiens gene expression array.

2007-09-15 | E-GEOD-8533 | biostudies-arrayexpress

LNCAP/AR and a LnCAP/AR subline (LREX') with acquired resistance to 2nd generation antiandrogens

Project description:The treatment of advanced prostate cancer has been transformed by novel antiandrogen therapies such as enzalutamide. Using the LnCaP/AR xenograft model, we identified induction of glucocorticoid receptor (GR) expression as a common feature of drug resistant tumors. From a resistant xenograft tumor, we derived a GR expressing resistant subline called LREX' which maintains the resistant phenotype. mRNA expression was used to characterize resistant tissues. LnCaP/AR cells were injected into castrate mice and tumors were established. Mice were then treated with vehicle (Con), 4 days of anti-androgen (ARN-509 10mgkg), or were maintained on anti-androgen (10mg/kg ARN-509 or enzalutamide) until emergence of resistance. Resistant tissues continued to be exposed to anti-androgen through time of harvest. LREX' (LnCaP/AR Resistant to Enzalutamide Xenograft Derived) was derived from an enzalutamide resistant xenograft and was re-injected into castrate mice undergoing continual treatment with enzalutamide. The GR probe on the Illumina array failed to detect GR expression. Therefore, GR expression as determined by qPCR is annotated separately. Of the 10 control tissues, 8 were analyzed twice (technical duplicates annotated as A and B).

2013-12-27 | E-GEOD-51873 | biostudies-arrayexpress

Gene expression of murine repeatedly activated Th1 cells after miR-31 knock down

Project description:Gene expression of murine repeatedly activated Th1 cells 36h, 48h and 72h after miR-31 inhibition using a specific antagomir (Antagomir-31) compared to a scrambled controll (Antagomir-SCR).

2018-12-19 | GSE122223 | GEO

R1881 treatment modulates LNCaP proteome.

Project description:The androgen receptor is considered as the key promoter of prostate cancer. It is a transcription factor that controls the transcription of hundreds of its target genes. In this project we focuses on how androgen receptor stimulation by the synthetic androgen R1881 can affect the proteome of peroxiosmes and the antioxidant enzymes in LNCaP cells.

2024-11-01 | PXD054374 | Pride

REST knockdown in LNCaP prostate cancer cells

Project description:LNCaP cells were transfected with 3 different REST siRNAs Transcriptomics analysis was performed to compare gene expression changes induced by REST knockdown Genome-wide transcriptomic analysis of LNCaP cells transfected with REST siRNA

2013-10-22 | E-GEOD-51461 | biostudies-arrayexpress

50uM Casodex treatment of PC-346C Prostate Cancer cells

Project description:Genome wide expression changes following 50uM Casodex treatment were investigated to determine regulatory targets commonly overlooked in gene function specific microarrays and for comparison of the effects the wild-type AR expressing PC-346C cells against the mutant androgen receptor (AR) LNCaP cell line. PC-346C Prostate Cancer cells were treated for a period of 48h with or without 50uM Casodex following a 36h seeding period. At the selected time point, total RNA was harvested from the cells for hybridization and analysis by Nimblgen Systems Inc using the homo sapiens gene expression array.

2007-09-15 | E-GEOD-8534 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data